Used in the treatment of certain T-cell lymphomas, including adult T-cell leukemia-lymphoma (ATLL) and cutaneous T-cell lymphoma (CTCL). It targets CCR4, a receptor expressed on the surface of malignant T-cells, enabling the immune system to destroy these cancer cells through antibody-dependent cellular cytotoxicity (ADCC). Approved in several countries for relapsed or refractory cases, it offers a targeted therapy option with clinical benefit in controlling disease progression. Also under investigation for other CCR4-positive malignancies and in combination with other immunotherapies.